GlassScriptPhysician profile
Julee Kauling
NPI 1437108909
$4,535.45
in general payments reported to CMS, 2019-2025
20 companies · $2,301 in 2025
The $2,301 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.61 · 2022: $492 · 2023: $797 · 2024: $867 · 2025: $2,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,952 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,952.25 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,190.26 | 2022-2025 | Caplyta |
| Abbvie INC. | $994.56 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $538.51 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $297.12 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $226.03 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $205.14 | 2021-2022 | |
| Braeburn INC. | $134.13 | 2025 | Brixadi |
| Tris Pharma INC | $132.35 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $124.56 | 2024 | Cobenfy |
| Alkermes, INC. | $122.64 | 2025 | Lybalvi |
| Corium, LLC | $104.74 | 2022-2024 | Azstarys |
| Indivior INC. | $103.48 | 2025 | Sublocade |
| Lundbeck LLC | $77.68 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $64.41 | 2023 | Ingrezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.26 | 2022 | |
| Noven Therapeutics, LLC | $14.91 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $13.75 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $12.00 | 2021 | |
| Neuronetics, INC. | $3.92 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julee Kauling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.